
Milan (Italy), May 16th, 2019 - MolMed S.p.A. (MLMD.MI) (the “Company”), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces that Riccardo Palmisano, CEO of the Company, has been reappointed President of Assobiotec for the three-year period 2019-22 during the annual Meeting of Assobiotec-Federchimica, held yesterday in Rome.

Assobiotec, the Italian Association for the development of Biotechnology, represents approximately 130 business and technology parks operating in Italy in the biotech field.

The Annual Meeting was also the occasion for the assignment today of the Assobiotec Award, now in its XII edition, and aimed to recognize personalities and/or entities that stood out in promoting innovation, scientific research and technology transfer in the biotechnology field.

Franco Locatelli, full professor of Pediatrics at the University “La Sapienza”, Roma, Director of the Department of Onco-Pediatric Hematology, Cell and Gene Therapy of the Bambino Gesù Children's Hospital of Rome, and, since February 2019, Director of the Italian Board of Health, received the Assobiotec Award 2019. Recognized at an international level as one of the main expert of onco-pediatric hematology, Professor Locatelli is appreciated, inter alia, for his important contribution to the study and trial of CAR-T therapies, the new immuno-oncology based on engineered T-lymphocytes, key area of research also of MolMed, giving new hope to cancer patients without other chance of treatment.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which on March 19th 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with
PRESS RELEASE

Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
+39 02 21277.205
investor.relations@molmed.com

Tommasina Cazzato
Press Office
Community Group
+39 345 7357751
tommasina.cazzato@communitygroup.it